Earnings Call · Q1 FY2022·2022-05-05

Q1 22EPS +1.14%·Rev n/aQ4 21EPS -2.96%·Rev n/aQ3 21EPS +3.82%·Rev n/aQ2 21EPS -8.59%·Rev n/a⚠ consensus missing

AGIOS PHARMACEUTICALS, INC. AGIO

Holly Manning — Investor Relations

Jackie Fouse — Chief Executive Officer

Sarah Gheuens — Clinical Team Leader/Executive

Richa Poddar — Commercial/Marketing Executive

Jonathan Biller — Chief Financial Officer

−4.7%1d on move date−1.2% vs SPY3d−15.4%5d−15.1%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AGIO calls or request research access.

More AGIO calls Browse calls Request research access